Join HiFiBiO Therapeutics CEO Liang Schweizer at the Fierce 15 – Where are They Now? panel at the Fierce Biotech Summit 2024 in Boston on September 30 at 4:45pm EDT!?? ? We are excited to participate in the exciting discussions on the evolving biotech landscape and how leaders in the field are shaping the future of the industry. #biotech #innovation #leadership
HiFiBiO Therapeutics
生物技术
Cambridge，Massachusetts 8,438 位关注者
HiFiBiO Therapeutics is a clinical stage biotherapeutics company mobilizing the human immune system to combat disease.
关于我们
HiFiBiO Therapeutics is a clinical-stage global biotech pioneering a unique high-resolution translational solution (DIS?, Drug Intelligence Science) to enhance the probability of success for immunotherapies. DIS? combines unique single-cell capabilities with AI/ML approaches using patient samples to discover novel targets, effective antibody drugs, and predictive biomarkers. With DIS?, HiFiBiO gains an unprecedented understanding of immune modulation in human diseases driving a robust clinical pipeline of transformative immunotherapies. Additionally, HiFiBiO has partnered with major multinational pharmaceutical and biotech companies applying its innovative DIS? approach. HiFiBiO Therapeutics is headquartered in Cambridge, MA with additional operations in Paris, France, Hong Kong, Shanghai, and Hangzhou, China.
- 网站
-
https://www.hifibio.com
HiFiBiO Therapeutics的外部链接
- 所属行业
- 生物技术
- 规模
- 51-200 人
- 总部
- Cambridge，Massachusetts
- 类型
- 私人持股
- 创立
- 2013
- 领域
- Microfluidics、Single-cell、Antibodies、Therapeutics、drug discovery、Target discovery、biomarker discovery、artificial intelligence、machine learning和immune modulation
地点
HiFiBiO Therapeutics员工
动态
-
Exciting news!?Join us at the #BiotechWeekBoston (BWB) Awards?next?Monday,?September 23,?where we’re honored to be?among the?finalists?for the?Start-up of the Year Award! We’re also thrilled to announce that?our CEO, Liang Schweizer, is named?a Finalist for the?prestigious?Lifetime Achievement Award.?? ? Under Liang’s?visionary?leadership, our passionate team has advanced a diverse portfolio of cutting-edge immunotherapies targeting cancers and autoimmune diseases, including three novel IO programs into Phase I. Furthermore, our single-cell and AI/ML powered Drug Intelligence Science (DIS?) translational platform represents a significant leap forward in precision medicine, allowing for more tailored therapies for individual patients and maximizing clinical success rates.? ? Click here to register for the event:?https://lnkd.in/ehi_EvwZ ? #biotech #immunotherapy #innovation #DrugIntelligenceScience #leadership?#BWB #StartupoftheYear #PrecisionMedicine #AI #CancerTherapies
-
-
Our team enjoyed the exciting conversations around our two posters at #ESMO2024! We were thrilled to share the promising Ph1 clinical trial results for HFB200301, a first-in-class TNFR2 agonist and HFB200603, a best-in-class BTLA antagonist in DIS(R)-selected solid tumors ? The full posters are up on our website for viewing: ? HFB200301: https://lnkd.in/eCA3uZnq HFB200603: https://lnkd.in/ebVAug3y
-
-
Reminder to stop by our two posters at #ESMO2024! HiFiBiO Therapeutics will present interim Phase 1 clinical data for two novel immuno-oncology programs: a first-in-class TNFR2 agonist HFB200301 and a best-in-class BTLA antagonist HFB200603.?These programs have shown promise both as monotherapy and in combination with anti-PD-1, demonstrating the capability to elicit a robust anti-cancer immune response, even in IO refractory tumors.? ? Link to press release and abstract: https://lnkd.in/eFgCHPxJ? ? #cancer #immunotherapy #innovation?
-
-
Reminder to stop by our two posters at #ESMO2024! HiFiBiO Therapeutics will present interim Phase 1 clinical data for two novel immuno-oncology programs: a first-in-class TNFR2 agonist HFB200301 and a best-in-class BTLA antagonist HFB200603.?These programs have shown promise both as monotherapy and in combination with anti-PD-1, demonstrating the capability to elicit a robust anti-cancer immune response, even in IO refractory tumors.? ? Link to press release and abstract: https://lnkd.in/eFgCHPxJ? ? #cancer #immunotherapy #innovation?
-
-
HiFiBiO Therapeutics, a leading clinical stage immune modulation company, announced today its participation in the #ESMO2024 meeting, taking place Sep 13-17 in Barcelona, Spain. On Saturday, September 14, the company will present compelling Phase 1 trial data for two novel monoclonal antibodies: a first-in-class TNFR2 agonist HFB200301 (NCT05238883) and a best-in-class BTLA antagonist HFB200603 (NCT05789069).? ? Come visit our posters to learn more about these two programs and their therapeutic potential in IO refractory tumors! View full press release here: https://lnkd.in/eFgCHPxJ ? #cancer #aiandml #immunooncology #immunotherapy #innovation ?
-
-
We are thrilled that HiFiBiO Therapeutics has been recognized as a Finalist for the Start-up of the Year Award, and its CEO, Liang Schweizer, has been selected as a Finalist for the Lifetime Achievement Award at #BiotechWeekBoston!?? Under Liang’s leadership, our passionate team has advanced a diverse portfolio of best-in-class and first-in-class immunotherapies, including three novel IO programs into Phase I. Furthermore, our single-cell and AI/ML powered Drug Intelligence Science (DIS?) translational platform provides unique, high resolution insights into patient immunobiology and disease mechanisms to maximize clinical benefit.?? #biotech #immunotherapy #innovation #DrugIntelligenceScience??
-
-
We are excited to welcome Carl Liederman to our Board of Directors! Carl is a prominent leader in Corporate and Legal Strategy with over 30 years of experience in VC, Cross-border M&A, PE, Capital Markets, Healthcare (Pharma, Medtech, and Biotech),?and Impact and Sustainability. His deep experience will bring tremendous value as we continue our journey as a leading immune modulation biotech.
-
-
Proud to have our CEO Liang Schweizer selected as a winner in the Entrepreneur Of The Year? New England program!?She joins an esteemed multi-industry community of other entrepreneurs who have driven their companies’ success, transformed their industries, and made a positive impact on their employees and communities! https://lnkd.in/eJ3BhqJS #EOYUS #EOYNE
-
June is #NationalCancerSurvivorMonth. Join HiFiBiO Therapeutics in honoring the over 18 million individuals in the U.S. living with a history of cancer and the unique challenges they continue to face (AACR https://lnkd.in/g-p7KKU). Thanks to remarkable advances in cancer research, there have been significant improvements in cancer diagnostics and treatment, particularly in the field of cancer immunotherapies. However, substantial gaps remain. Many patients harbor cancers that either do not respond to current standard immunotherapies or experience relapse, limiting the potential benefits (https://lnkd.in/ezt2uiyf). HiFiBiO Therapeutics is utilizing its DIS? translational platform to develop a pipeline of novel immune modulatory therapeutics aimed at overcoming these gaps. The company has advanced three cancer immunotherapies into Phase I trials, showing promising developments: the first-in-class anti-TNFR2 antibody HFB200301 (clinical trial NCT05238883), the next-generation OX40 agonist antibody HFB301001 (clinical trial NCT05229601), and the best-in-class BTLA antagonist antibody HFB200603 (clinical trial NCT05789069).? ? #hifibioway #cancer #cancerawareness #cancertreatment #cancersurvivor #innovation #immunotherapy?
-